Biogen Inc. (BMV:BIIB)

Market Cap	488.78B +13.5%
Revenue (ttm)	178.06B +2.2%
Net Income	23.28B -20.8%
EPS	158.25 -21.4%
Shares Out	n/a
PE Ratio	21.00
Forward PE	12.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Average Volume	91
Open	3,125.00
Previous Close	3,265.00
Day's Range	3,125.00 - 3,125.00
52-Week Range	2,395.00 - 3,356.00
Beta	0.16
RSI	54.66
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BIIB

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD